## AAPG: Ascentage Pharma Group Internat - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -5.0% below STRENGTH zone (3.0-6.0%); PEG unavailable fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-3.2% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($28.34)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 1
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Ascentage Pharma Announces Global Registrational Phase III Study of Olverembatinib in First-Line Treatment of Ph+ ALL Cleared by US FDA and EMA**
- Source: GlobeNewswire | 20251204T190000 | Bullish | Relevance: 100%
- Ascentage Pharma has received clearance from the US FDA and EMA for a global registrational Phase III study (POLARIS-1) of olverembatinib in combination with chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The study is simultaneously enrolling patients globally to accelerate olverembatinibâ€™s path to registration, with initial data showing promising MRD negativity rates and favorable safety. This marks a significant step in addressing unmet clinical needs in Ph+ ALL, building on olverembatinib's prior approvals in China for CML.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-04 | Oppenheimer | $45 | $0 | 0% |
| 2025-11-24 | Truist Securiti | $51 | $0 | 0% |
| 2025-11-10 | BTIG | $50 | $0 | 0% |
| 2025-11-05 | Piper Sandler | $48 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-04 | Oppenheimer | init | Outperform |
| 2025-11-24 | Truist Securiti | init | Buy |
| 2025-11-10 | BTIG | init | Buy |
| 2025-11-05 | Piper Sandler | init | Overweight |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 0.1% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- UBS Group AG: 0.0% (+149.4%)
- XY Capital Ltd: 0.0% (+224.1%)
- Point72 (DIFC) Ltd: 0.0% (-14.2%)
- Tema Etfs LLC       : 0.0% (-33.0%)
- ABC Arbitrage SA: 0.0% (+100.0%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

Revenue growth strong at 227% YoY. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $2.6B |
| Beta | 1.11 |
| 52W Range | $16.50 - $48.45 |
| Short Interest | 0.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | N/A |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_10 deteriorating from -1.8% to -5.0% (-3.2% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 8.0pp (needs >3.0% for momentum thesis). Underperforming sector by 3.6pp, stock-specific weakness. Below SMA200 (0.97x), long-term trend not supportive. OFD pattern: -SUL (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -5.04% (CS: 5) | Weak |
| RSI_14 | 38.8 | Neutral |
| MACD Histogram | 0.03 | Bullish |
| vs SMA20 | 0.954x | Below |
| vs SMA50 | 0.889x | Below |
| vs SMA200 | 0.967x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $30.70
- **Stop Loss:** $28.34 (7.7% risk)
- **Target:** $33.06 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 211
- **Position Value:** $6,477.70
- **Portfolio %:** 6.48%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with moderate risk appetite and mixed signals. VIX at 15.78 indicates calm conditions but breadth at 53% suggests narrow participation. Fed policy remains neutral with 42 days to next meeting, supporting steady positioning with sector selectivity.*

### Earnings

**Next:** 2026-03-26 (Est: $0.00)

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_10*